Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-07: A Phase 1/2 Study of CD22-Specific CAR T Cells for CD22+ Leukemia or Lymphoma
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 35
- 试验地点
- 4
- 主要终点
- The adverse events associated with CAR T cell product infusions will be assessed
研究概览
简要总结
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a chimeric antigen receptor (CAR). The CAR used in this study can recognize CD22, a protein expressed on the surface of leukemia and lymphoma cells. The phase 1 part of this study will determine the safety and appropriate dose level of these CAR T cells, and the phase 2 part of the study will determine how effective this CAR T cell therapy is. Both patients who have never had prior CAR T cell therapy and those who have had prior CAR T cell therapy may be eligible to participate in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects aged ≤ 30 years. First 2 enrolled subjects: age ≥ 18 and ≤ 30 years
- •Evidence of refractory or recurrent CD22+ leukemia or lymphoma
- •Able to tolerate apheresis, or subject with sufficient existing apheresis product or T cells for manufacturing investigational product.
- •Life expectancy ≥ 8 weeks
- •Lansky or Karnofsky, as applicable, score ≥ 50
- •Recovered from acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy, if the subject does not have a previously obtained apheresis product that is acceptable and available for manufacturing of CAR T cells
- •≥ 7 days post last chemotherapy and biologic therapy, with the exception of intrathecal chemotherapy and maintenance chemotherapy
- •≥ 7 days post last corticosteroid therapy
- •≥ 3 days post Tyrosine Kinase Inhibitor (TKI) use
- •≥ 1 day post hydroxyurea
- •30 days post most recent CAR T cell infusion
- •Adequate organ function
- •Adequate laboratory values, including absolute lymphocyte count ≥ 100 cells/uL
- •Subjects of childbearing or child-fathering potential must agree to use highly effective contraception from consent through 12 months following infusion of investigational product on trial
- •Subject and/or legally authorized representative has signed the informed consent form for this study
排除标准
- •Presence of active malignancy other than disease under study
- •History of symptomatic CNS pathology or ongoing symptomatic CNS pathology
- •CNS involvement of leukemia or lymphoma that is symptomatic and in the opinion of the investigator, cannot be controlled during the interval between enrollment and CAR T cell infusion
- •Subjects with uniform expression of CD19 on their malignant cells who are eligible but have not attempted CD19 directed CAR T cell therapy
- •For subjects having had a previous stem cell transplant: presence of active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment
- •Presence of active severe infection,
- •Presence of primary immunodeficiency syndrome
- •Subject has received prior virotherapy
- •Pregnant or breastfeeding
- •Subject and/or legally authorized representative unwilling to provide consent/assent for participation in the 15-year follow-up period, required if CAR T cell therapy is administered
- •Presence of any condition that, in the opinion of the investigator, would prohibit the subject from undergoing treatment under this protocol
研究组 & 干预措施
SCRI-CAR22v2
Patients will receive SCRI-CAR22v2 in either Phase I or Phase II
干预措施: SCRI-CAR22v2 (Biological)
结局指标
主要结局
The adverse events associated with CAR T cell product infusions will be assessed
时间窗: 28 days post-infusion
The type, frequency, severity, and duration of adverse events will be summarized
The ability to successfully manufacture SCRI-CAR22v2
时间窗: 28 days
We will measure the number of successfully manufactured SCRI-CAR22v2 products
The leukemia response to SCRI-CAR22v2 in subjects with relapsed or refractory CD22+ leukemia will be assessed
时间窗: 28 days post-infusion
The efficacy of the T cell infusion will be estimated based on the number of participants who have an MRD negative bone marrow aspirate following the T cell infusion
Dose Limiting Toxicities
时间窗: 28 days post-infusion
Number of participants who experienced an adverse event meeting the dose-limiting toxicity definition
The Ability to Successfully Manufacture SCRI-CAR22v2
时间窗: 28 days
Number of participants who have a releasable cell product generated
The Leukemia Response to SCRI-CAR22v2 in Subjects With Relapsed or Refractory CD22+ Leukemia Will be Assessed
时间窗: 28 days post-infusion
Number of participants with an MRD negative complete remission after initial CAR T cell infusion (by Day 28 post infusion assessment +/- 3 Days)
次要结局
未报告次要终点
研究者
Colleen Annesley
Medical Director, Seattle Children's Therapeutics
Seattle Children's Hospital